NIPC Law

Author RickDikeman   Licence CC BY-SA 3.0   Source Wikimedia Commons     Jane Lambert Patents Court (David Stone) Networld Sports Ltd v Quick Play Sport Ltd [2026] EWHC 1295 (Ch) (1 June 2026) This was an appeal by Networld Sports Ltd ("Networld") against the decision of Dr Benjamin Micklewright on behalf of the Comptroller General of Patents, Designs and Trade Marks of 14 Oct 2025 not to revoke claims 1 and 10 of  European patent (UK) 2 146 786 B1  on grounds of anticipation and obviousness.  The appeal was heard by Mr David Stone sitting as a deputy judge of the High Court on 9 March 2026.  Mr Stone handed down his judgment on 1 June 2026.  By para [43] of his judgment in  Networld Sports Ltd v Quick Play Sport Ltd [2026] EWHC 1295 (Ch) (1 June 2026), he dismissed Networld's appeal. The Invention The title of the patent was "Goal Apparatus".   It consisted of a  frame,  first and second flexible ...

Human Respiratory Syncytial Virus Author NIAID   Licence CC BY 2.0   Source    Wikimedia Commons   Jane Lambert Patents Court (Mr Justice Mellor)  Pfizer Ltd v GlaxoSmithKline Biologicals SA and another 2024] EWHC 2523 (Pat) (07 Oct 202 4) Pfizer Ltd v GlaxoSmithKline Biologicals SA and anothe r [2025] EWHC 52 (Pat) (16 Jan 2025) This was a claim by Pfizer Ltd. ("Pfizer")  for the revocation of  EP (UK) 3 109 258 ("258") and EP (UK) 2 222 710 ("710")  under s.72 (1) (a)  of the Patents Act 1977 on the grounds that the inventions for which those patents were granted were not patentable.  The patents were held by  GlaxoSmithKline Biologicals SA  and  ID Biomedical Corporation of Quebec  (collectively "GSK").   The reason for the litigation was that both Pfizer and GSK had developed vaccines for respiratory syncytial virus ("RSV")  that were about to receive marketing approval in the UK....

Omalizumab structure Authors  Manav Segal, Jeffrey R Stokes, Thomas B. Casale Licence CC BY 2,5 Source Wikimedia Commons Jane Lambert Patents Court (HH Judge Hacon)  Celltrion Inc v Genentech, Inc and another [2025] EWHC 174 (Pat) (30 Jan 2025)   This was an action by Celltrion Inc ("Celltrion") for the revocation of European patent (UK)  3 805 248 B1  for a "Process for concentration of antibodies and therapeutic products thereof" ("the patent") held by Genentech Inc ("Genentech") and Novartis AG ("Novartis") and a counterclaim by Genentech and Novartis against Celltrion and its UK subsidiary for infringement.  The action and counterclaim were tried by His Honour Judge Hacon between 24 Oct 2024 and 1 Nov 2024.  The learned judge delivered judgment on 30 Jan 2025 (see  Celltrion Inc v Genentech, Inc and another  [2025] EWHC 174 (Pat) (30 Jan 2025)).  By para [193] of his judgment, he found that the patent was valid and infringed. Th...